Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma.
Peter Borchmann, MD
Advertisement
Articles by Peter Borchmann, MD
Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses the updated analysis of the JULIET trial in patients with diffuse large B-cell lymphoma (DLBCL).
Advertisement
Latest Updated Articles
Dr. Borchmann Discusses the Updated Analysis of JULIET in DLBCLPublished: June 21st 2018 | Updated:
Dr. Borchmann on Next Steps With Tisagenlecleucel in DLBCLPublished: September 10th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
5